Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clostridium difficile | 11 | 2016 | 22 | 3.320 |
Why?
|
| Clostridium Infections | 7 | 2019 | 11 | 2.580 |
Why?
|
| Enterocolitis, Pseudomembranous | 6 | 2015 | 13 | 2.050 |
Why?
|
| Cross Infection | 7 | 2019 | 27 | 1.690 |
Why?
|
| Analgesics, Opioid | 3 | 2021 | 243 | 0.880 |
Why?
|
| Health Personnel | 5 | 2022 | 124 | 0.850 |
Why?
|
| Humans | 41 | 2025 | 17611 | 0.790 |
Why?
|
| Adult | 24 | 2023 | 7598 | 0.750 |
Why?
|
| Accelerometry | 1 | 2021 | 38 | 0.730 |
Why?
|
| Young Adult | 13 | 2021 | 2427 | 0.690 |
Why?
|
| Vaccination | 6 | 2025 | 635 | 0.660 |
Why?
|
| Pericarditis | 2 | 2018 | 11 | 0.650 |
Why?
|
| Myocarditis | 2 | 2018 | 14 | 0.610 |
Why?
|
| Incidence | 9 | 2022 | 1255 | 0.610 |
Why?
|
| Health Services | 2 | 2016 | 112 | 0.610 |
Why?
|
| Viral Vaccines | 1 | 2018 | 12 | 0.600 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 167 | 0.600 |
Why?
|
| Vaccines, Attenuated | 1 | 2018 | 45 | 0.600 |
Why?
|
| Health Services for the Aged | 1 | 2018 | 14 | 0.600 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 18 | 0.600 |
Why?
|
| Population Surveillance | 3 | 2014 | 263 | 0.600 |
Why?
|
| Male | 25 | 2025 | 10008 | 0.600 |
Why?
|
| Deprescriptions | 1 | 2018 | 8 | 0.600 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 39 | 0.580 |
Why?
|
| Female | 26 | 2025 | 12608 | 0.570 |
Why?
|
| Patient Education as Topic | 2 | 2018 | 211 | 0.560 |
Why?
|
| Middle Aged | 19 | 2022 | 7911 | 0.540 |
Why?
|
| Exercise | 1 | 2021 | 489 | 0.530 |
Why?
|
| Public Health Surveillance | 2 | 2022 | 42 | 0.530 |
Why?
|
| Risk Management | 1 | 2016 | 3 | 0.530 |
Why?
|
| Ambulatory Care | 2 | 2015 | 244 | 0.530 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 14 | 0.520 |
Why?
|
| Patient-Centered Care | 2 | 2017 | 197 | 0.520 |
Why?
|
| Aged | 15 | 2022 | 6095 | 0.500 |
Why?
|
| Medication Adherence | 2 | 2017 | 244 | 0.500 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 289 | 0.500 |
Why?
|
| Risk | 2 | 2022 | 516 | 0.480 |
Why?
|
| Decision Making | 2 | 2017 | 183 | 0.460 |
Why?
|
| Retrospective Studies | 9 | 2022 | 2447 | 0.430 |
Why?
|
| Community-Acquired Infections | 2 | 2019 | 23 | 0.420 |
Why?
|
| Adolescent | 14 | 2021 | 3651 | 0.420 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 212 | 0.400 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 69 | 0.400 |
Why?
|
| Health Expenditures | 1 | 2012 | 75 | 0.390 |
Why?
|
| Viral Load | 2 | 2022 | 135 | 0.380 |
Why?
|
| Northwestern United States | 4 | 2021 | 53 | 0.370 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 415 | 0.370 |
Why?
|
| Aged, 80 and over | 6 | 2022 | 1900 | 0.350 |
Why?
|
| Anti-Bacterial Agents | 4 | 2016 | 140 | 0.320 |
Why?
|
| Colorado | 3 | 2014 | 163 | 0.310 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2010 | 136 | 0.310 |
Why?
|
| Personnel, Hospital | 1 | 2008 | 9 | 0.300 |
Why?
|
| Anti-Infective Agents | 3 | 2016 | 15 | 0.300 |
Why?
|
| Hospitals, Rural | 1 | 2007 | 6 | 0.300 |
Why?
|
| Hospitalization | 5 | 2022 | 797 | 0.280 |
Why?
|
| Qualitative Research | 2 | 2018 | 254 | 0.280 |
Why?
|
| Influenza Vaccines | 1 | 2008 | 267 | 0.240 |
Why?
|
| Emergency Responders | 2 | 2021 | 4 | 0.240 |
Why?
|
| Risk Factors | 5 | 2023 | 3325 | 0.240 |
Why?
|
| Pharmacists | 2 | 2021 | 48 | 0.230 |
Why?
|
| Influenza, Human | 2 | 2022 | 263 | 0.220 |
Why?
|
| Case-Control Studies | 5 | 2019 | 1115 | 0.220 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 709 | 0.210 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 21 | 0.210 |
Why?
|
| United States | 8 | 2025 | 3956 | 0.200 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 44 | 0.200 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2014 | 228 | 0.200 |
Why?
|
| Prospective Studies | 7 | 2023 | 1267 | 0.200 |
Why?
|
| Vancomycin | 2 | 2012 | 3 | 0.200 |
Why?
|
| Cohort Studies | 4 | 2025 | 2570 | 0.200 |
Why?
|
| Angioedema | 1 | 2021 | 6 | 0.200 |
Why?
|
| Infant | 4 | 2025 | 1171 | 0.190 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 1309 | 0.190 |
Why?
|
| Occupations | 1 | 2021 | 16 | 0.190 |
Why?
|
| Pharmacy | 1 | 2021 | 12 | 0.190 |
Why?
|
| Vital Signs | 1 | 2021 | 13 | 0.190 |
Why?
|
| Occupational Diseases | 1 | 2021 | 41 | 0.190 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 238 | 0.180 |
Why?
|
| Physicians | 1 | 2021 | 137 | 0.180 |
Why?
|
| Time Factors | 4 | 2022 | 1086 | 0.180 |
Why?
|
| Odds Ratio | 2 | 2012 | 671 | 0.170 |
Why?
|
| Patient Participation | 1 | 2021 | 133 | 0.170 |
Why?
|
| Chronic Disease | 3 | 2019 | 428 | 0.170 |
Why?
|
| Veterans Health | 1 | 2019 | 21 | 0.170 |
Why?
|
| Logistic Models | 3 | 2015 | 926 | 0.170 |
Why?
|
| Communication | 1 | 2021 | 194 | 0.160 |
Why?
|
| Railroads | 1 | 2019 | 4 | 0.160 |
Why?
|
| Child, Preschool | 3 | 2025 | 1409 | 0.160 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 127 | 0.160 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 381 | 0.160 |
Why?
|
| Syncope | 1 | 2018 | 12 | 0.150 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2018 | 9 | 0.150 |
Why?
|
| Acute Pain | 1 | 2018 | 11 | 0.150 |
Why?
|
| Environment Design | 1 | 2019 | 64 | 0.150 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2018 | 17 | 0.150 |
Why?
|
| Length of Stay | 2 | 2010 | 181 | 0.150 |
Why?
|
| Health Surveys | 1 | 2019 | 260 | 0.150 |
Why?
|
| Life Change Events | 1 | 2018 | 31 | 0.150 |
Why?
|
| Infection Control | 2 | 2007 | 10 | 0.150 |
Why?
|
| Adolescent Health Services | 1 | 2018 | 43 | 0.150 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2016 | 2 | 0.140 |
Why?
|
| Child Health Services | 1 | 2018 | 113 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 211 | 0.140 |
Why?
|
| Electronic Health Records | 3 | 2019 | 681 | 0.140 |
Why?
|
| Child | 5 | 2023 | 2474 | 0.130 |
Why?
|
| Recurrence | 1 | 2016 | 186 | 0.130 |
Why?
|
| Heart Failure | 1 | 2021 | 396 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2022 | 1097 | 0.130 |
Why?
|
| Trimethoprim | 1 | 2015 | 4 | 0.130 |
Why?
|
| Sulfonamides | 1 | 2015 | 14 | 0.130 |
Why?
|
| Mental Health Services | 1 | 2018 | 154 | 0.130 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2015 | 15 | 0.130 |
Why?
|
| Patient Admission | 1 | 2016 | 72 | 0.130 |
Why?
|
| Pregnancy Trimester, First | 1 | 2015 | 39 | 0.130 |
Why?
|
| Forecasting | 1 | 2016 | 75 | 0.130 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2015 | 3 | 0.130 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 187 | 0.120 |
Why?
|
| Vaccines | 1 | 2018 | 212 | 0.120 |
Why?
|
| Algorithms | 1 | 2016 | 233 | 0.120 |
Why?
|
| Self Administration | 1 | 2014 | 9 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2016 | 177 | 0.120 |
Why?
|
| Electronic Mail | 1 | 2014 | 51 | 0.120 |
Why?
|
| Quality of Life | 1 | 2018 | 507 | 0.120 |
Why?
|
| Inpatients | 1 | 2014 | 81 | 0.110 |
Why?
|
| Outpatients | 1 | 2014 | 107 | 0.110 |
Why?
|
| Telephone | 1 | 2014 | 161 | 0.110 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2015 | 160 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2015 | 309 | 0.110 |
Why?
|
| Prognosis | 1 | 2014 | 606 | 0.110 |
Why?
|
| Comorbidity | 1 | 2014 | 594 | 0.100 |
Why?
|
| Metronidazole | 1 | 2012 | 4 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2012 | 237 | 0.100 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 34 | 0.100 |
Why?
|
| Iowa | 2 | 2007 | 38 | 0.090 |
Why?
|
| Delivery, Obstetric | 1 | 2010 | 16 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2011 | 151 | 0.090 |
Why?
|
| California | 1 | 2016 | 2284 | 0.090 |
Why?
|
| Pregnancy | 2 | 2015 | 1494 | 0.080 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2008 | 2 | 0.080 |
Why?
|
| Hospitals, University | 1 | 2008 | 16 | 0.080 |
Why?
|
| Administrative Personnel | 1 | 2008 | 6 | 0.080 |
Why?
|
| Infection Control Practitioners | 1 | 2007 | 1 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 36 | 0.070 |
Why?
|
| Immunization Programs | 1 | 2008 | 64 | 0.070 |
Why?
|
| Borrelia burgdorferi Group | 2 | 1998 | 2 | 0.070 |
Why?
|
| Lyme Disease | 2 | 1998 | 4 | 0.070 |
Why?
|
| DNA, Bacterial | 2 | 1998 | 8 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2018 | 114 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 375 | 0.060 |
Why?
|
| Arthritis, Infectious | 1 | 1982 | 1 | 0.050 |
Why?
|
| Yersinia Infections | 1 | 1982 | 1 | 0.050 |
Why?
|
| Arthritis, Reactive | 1 | 1982 | 1 | 0.050 |
Why?
|
| Primary Health Care | 2 | 2021 | 766 | 0.050 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2022 | 3 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2022 | 7 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2022 | 5 | 0.050 |
Why?
|
| Thrombosis | 1 | 2022 | 11 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2022 | 64 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2022 | 32 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 6 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 65 | 0.050 |
Why?
|
| Carrier State | 1 | 2021 | 8 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 7 | 0.050 |
Why?
|
| Internet | 1 | 2023 | 231 | 0.050 |
Why?
|
| Sacrococcygeal Region | 1 | 2001 | 1 | 0.050 |
Why?
|
| Diskectomy | 1 | 2001 | 2 | 0.050 |
Why?
|
| Prednisolone | 1 | 2001 | 3 | 0.050 |
Why?
|
| Sciatica | 1 | 2001 | 2 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2001 | 3 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2001 | 17 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 86 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2021 | 1259 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 382 | 0.040 |
Why?
|
| Oregon | 1 | 2019 | 171 | 0.040 |
Why?
|
| Patient Comfort | 1 | 2018 | 3 | 0.040 |
Why?
|
| Fibromyalgia | 1 | 1998 | 4 | 0.040 |
Why?
|
| Cryotherapy | 1 | 2018 | 4 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 1998 | 33 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 35 | 0.040 |
Why?
|
| Nails, Malformed | 1 | 1997 | 2 | 0.040 |
Why?
|
| Pain Management | 1 | 2018 | 58 | 0.040 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1997 | 23 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2018 | 218 | 0.040 |
Why?
|
| Child Abuse | 1 | 2018 | 43 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2018 | 297 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 248 | 0.030 |
Why?
|
| Motivational Interviewing | 1 | 2017 | 33 | 0.030 |
Why?
|
| Synovial Membrane | 1 | 1996 | 1 | 0.030 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2017 | 102 | 0.030 |
Why?
|
| Parents | 1 | 2018 | 296 | 0.030 |
Why?
|
| Pharmacoepidemiology | 1 | 2015 | 18 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 85 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 330 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 844 | 0.030 |
Why?
|
| Prevalence | 1 | 2015 | 884 | 0.030 |
Why?
|
| Hypertension | 1 | 2017 | 500 | 0.030 |
Why?
|
| Ohio | 1 | 2011 | 23 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 85 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 102 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 89 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2011 | 127 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 231 | 0.020 |
Why?
|
| Disease Notification | 1 | 2007 | 7 | 0.020 |
Why?
|
| Health Resources | 1 | 2007 | 37 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 49 | 0.020 |
Why?
|
| Hospitals | 1 | 2007 | 80 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 256 | 0.020 |
Why?
|
| Endocarditis | 1 | 1982 | 1 | 0.010 |
Why?
|
| Yersinia enterocolitica | 1 | 1982 | 1 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1982 | 32 | 0.010 |
Why?
|
| Epidural Space | 1 | 2001 | 2 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2001 | 3 | 0.010 |
Why?
|
| Injections, Epidural | 1 | 2001 | 6 | 0.010 |
Why?
|
| Fibrosis | 1 | 2001 | 7 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2001 | 155 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 1998 | 33 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1996 | 1 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1996 | 1 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1996 | 2 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 3 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 19 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 17 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1996 | 20 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1996 | 304 | 0.010 |
Why?
|
Concepts
(224)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(24)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->